eli lilly and company - Search News

Weight Loss Drug Demand Drives Eli Lilly Sales

Hosted on MSN · 1d

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

U.S. News & World Report · 1d

Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast

Business Insider · 1d

Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become

Eli Lilly Stock Rises

Kiplinger on MSN · 1d

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

Investopedia on MSN · 2d

What Analysts Think of Eli Lilly Stock Ahead of Earnings

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly reports mixed earnings, increases 2025 guidance

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 billion.

21h

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Inside Eli Lilly’s bold breast cancer awareness ad debut at the Grammys

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

2d

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

1don MSN

Here’s Why Eli Lilly (LLY) Traded Down in Q4

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Lilly expands GLP-1 research to hypertension, neuro conditions

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

11h

Citi Keeps Their Buy Rating on Eli Lilly & Co (LLY)

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

FierceBiotech1d

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results